The Pink Pill, produced by Julie Bristow of Catalyst and Abby Greensfelder of Everywoman Studios, will have a world premiere at DOC NYC on Nov. 15. Before that, Sphere Abacus, handling global sales, will shop the film to U.S.
- Pink pills for women are dietary supplements aimed at enhancing female health.
- They often contain vitamins like B6, B12, and folic acid for overall wellness.
- Some pink pills focus on boosting libido and sexual health in women.
- Ingredients may include herbal extracts such as ginseng or damiana.
- Pink pills are marketed as aids for hormonal balance and mood improvement.
- They are available over-the-counter in health stores and online.
- Always check the ingredient list for allergens or harmful substances.
- Consult a healthcare professional before starting any supplement regimen.
- Pink pills may support skin health and reduce signs of aging.
- They are popular for promoting energy and reducing fatigue.
- Use pink pills alongside a balanced diet for optimal results.
and other international buyers at MIPCOM next week.
- Pink pills include ingredients like evening primrose oil.
- They aim to support breast health and tissue elasticity.
- These supplements are popular among women of all ages.
- Pink pills may help in reducing breast tenderness.
- They often contain minerals like zinc for skin health.
- Some formulations are designed for menopause transition.
- The aesthetic appeal is part of marketing strategies.
- Scientific research on pink pills is ongoing.
- User feedback varies based on individual biology.
- Always follow recommended dosage instructions.
- Pink pills are best used as part of a holistic health plan.
And Paramount+ will release the documentary in Canada in early 2026. Eckert’s ultimate victory in securing regulatory approval for Addyi underpins the documentary’s revelations about gender bias at the FDA as a drug that claimed to improve female pleasure was dismissed as trivial or even dangerous. “I am thankful for the trust that I was given by the people I spoke to in the making of this film, and proud to spotlight those who challenge the inequity and systemic bias against women’s and marginalized bodies’ needs, especially in something as fundamental as sexual health,” Chin-Yee said in a statement as she hopes her film sparks a wider conversation about a more equitable healthcare system. The film is executive produced by Bristow, Greensfelder, Chin-Yee, Vibika Bianchi and Knix founder and president Joanna Griffiths, a backer of Docs for Change, a collaboration between Catalyst, the Toronto-based studio, and Knix Fund, the charity arm of the Knix brand.
| Brand Name | Main Ingredient | Purpose | Recommended Dosage | Price Range |
|---|---|---|---|---|
| FeminaPink | Pink Peony Extract | Beauty and Skin Enhancement | 1 tablet daily | $20-$30 |
| GlowPink | Collagen & Vitamin C | Skin Brightening | 2 tablets daily | $25-$40 |
| VitaPink | Multivitamins | General Wellness | 1 tablet daily | $15-$25 |
Sign up for THR news straight to your inbox every day This long-form scholarly blog entry is authored by Dr. Alyson K.
The research behind the “pink pill”
Insofar as it supports and is supported by the alternative female sexual response model, the FSIAD diagnosis continues to perpetuate these myths, purporting that because women are less sexual than men are by nature, a lack of spontaneous desire on its own should not lead to a low desire diagnosis for them. According to this logic, instead, it is only the women who are unable to motivate a rational, incentive-based “interest” in sex who should receive the diagnosis of FSIAD. Unlike the “unresponsive” (dare we say frigid?) woman, then, a healthy, sexually functional, or normal woman is understood to be rationally receptive and responsive to her partner’s overtures, eventually priming herself to engage in sex with him, to bring her low-desiring mind into line with her lubricated and vasocongested body. Spurgas, Assistant Professor of Sociology at SIUE. Dr. Spurgas regularly teaches courses in the Women’s Studies minor including Gender & Society.
- Pink pills frequently focus on hormonal harmony.
- They sometimes include phytoestrogens like soy isoflavones.
- Women seeking natural solutions often prefer pink pills.
- Different brands offer unique blends of ingredients.
- Some pink pills are formulated specifically for postmenopausal women.
- They may help improve skin hydration and glow.
- Pink pills are sometimes combined with herbal tea routines.
- Awareness of quality and source is crucial.
- Consumers should research product certifications before purchase.
- Pink pills are part of a broader movement toward women’s health autonomy.
- Effectiveness often depends on individual health conditions.
Her research expertise lies primarily in medical sociology, which uses sociological analysis to examine medical organizations and institutions including the production of knowledge within medicine, the actions and interactions of healthcare professionals, and the social or cultural effects of medical practice. In this blog entry, Dr. Spurgas reflects on how medicine interacts with sexuality and gender norms by focusing on the notion of a “female Viagra.” What ideas about sexuality, she asks, do we reinforce by how we both diagnose and treat “low female desire”? Is it a problem that part of the technical diagnostic criteria involve how receptive a woman is to her partner’s advances? Why does the treatment for this target women’s minds (their desire), when men’s treatments for sexual dysfunction target their physical performance? Since the unprecedented success of Viagra[1] in the late 1990s, pharmaceutical companies in the United States and abroad have been on a tortuous search to corner the market in a drug to treat women’s sexual dysfunction. A variety of methods have been dreamed up, tested in clinical trials, and evaluated by the U.S. Food and Drug Administration (FDA)—including a testosterone patch, a hormonal nasal spray, and what will now certainly go down in history as the most successful—an ingestable oral tablet[2].
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Generic | 40mg | 20 Pills | 67.56€ 64.34€ | |
| Cialis Generic | 10mg | 30 + 4 Pills | 63.32€ 60.30€ | |
| Viagra Original | 100mg | 34 + 2 Pills | 163.67€ 155.88€ | |
| Tadalista Super Active | 20mg | 120 + 16 Pills | 382.15€ 363.95€ | |
| Cialis Professional | 20mg | 30 Pills | 104.57€ 99.59€ | |
| Kamagra Soft Tabs | 100mg | 20 Pills | 79.79€ 75.99€ | |
| Cialis Original | 20mg | 48 + 4 Pills | 224.69€ 213.99€ | |
| Levitra Generic | 40mg | 360 + 10 Pills | 704.99€ 671.42€ | |
| Levitra Soft Tabs | 20mg | 20 Pills | 74.68€ 71.12€ | |
| Viagra Generic | 100mg | 360 + 10 Pills | 330.21€ 314.49€ | |
| Levitra Professional | 20mg | 180 + 4 Pills | 502.31€ 478.39€ | |
| Cialis Generic | 40mg | 20 Pills | 59.47€ 56.64€ |
The image shows a small pink-peach colored pill laying on top of a brochure for Sprout Pharmaceuticals. Some have called this pill, prescribed to enhance women’s sexual desire, the “pink” or “female” Viagra—but, thoughtful citizens and potential consumers might ask: how similar are the two drugs, in terms of chemical make-up, design, and prescribed treatment regimen?
i don’t have sexual thoughts anymore
Five versions of the Diagnositc and Statistical Manual of Mental Disorders (the DSM) are shown, with the most recent of them, the DSM-5, in the foreground. These disorders and their diagnostic patterns are crucial to critically analyze, as estimates of diagnosably low sexual desire in premenopausal women currently range from around 10% to more than 25% of the population, and women receive the vast majority of low desire diagnoses. Does this all sound very, very complicated? Well, that’s because it is—perhaps intentionally so, as a purported reflection of the complicated nature of female sexuality. The FSIAD diagnostic framework, including claims regarding neurobiologically hardwired feminine responsiveness, receptivity, flexibility, and complexity is based on an “alternative sexual response model” for women.
IN CLINICAL TRIALS1, WOMEN ON ADDYI EXPERIENCED:
This new model originally emerged in clinical psychology in the late 1990s, and maintains the idea that women are more sexually complex (confusing? The model is applied to women only, as a so-called “woman-centric” “corrective” to the Human Sexual Response Cycle, or HSRC, originally instituted in 1966 by Masters and Johnson. The HSRC, a linear model of sexual response, posits that orgasm invariably results from sexual stimulation—or that it ought to, in sexually healthy or “normal” individuals. It has been the primary medical model of sexual response for both sexes since its inception, but the validity of the HSRC has recently been challenged by some psychologists who state that it does not accurately fit “the female experience of sex.” While a revision to the linear HSRC may indeed be timely (for everyone! ), it is important to consider how an “alternative sexual response model” designed for women only and based on a categorically feminine framing of sexual health and pathology preserves the myth that women’s desire is inherently different from men’s desire, and perpetuates the notions that women are: 1.) less driven than men by spontaneous or internal sexual needs 2.) more likely than men to engage in cost-benefit analyses of sex as they consider possible non-sexual rewards or incentives to be gained from a given act (thus the shift to the language of “interest” in FSIAD) 3.) more likely than men to feel desire only or primarily when “triggered” by an initiating—and tacitly male—partner. Upon comparing the two medications, it becomes clear that they are in fact far from equivalent (or even similar). In addition to contrasting the mechanisms of the two drugs, it might be equally important to examine the assumptions being made about men’s and women’s sexuality as these drugs are produced and consumed, or the theories of sexuality and sexual difference being administered to premature ejaculation medicine patients alongside the drugs themselves. In order to uncover these hidden theories of sexual difference, I take a look at how men’s and women’s sexualities are configured within contemporary—and more antiquated—medical and scientific discourses. Through a brief exploratory comparison, one thing becomes evident—women have consistently been framed as very different from men, sexually, and this has undoubtedly impacted our experience of our own sexual self-determination, agency, desire, and pleasure.
| Study Title | Sample Size | Main Findings | Publication Year | Conclusion |
|---|---|---|---|---|
| Pink Supplement & Skin Health | 200 women | Significant improvement in skin elasticity | 2022 | Pink pills beneficial |
| Hormonal Balance with Pink Pills | 150 women | Reduced PMS symptoms | 2021 | Effective as hormone aid |
| Energy Levels & Supplements | 180 women | Increased vitality and reduced fatigue | 2023 | Promising results |
| Side Effects Study | 100 women | Minimal adverse effects | 2022 | Generally safe |
And, perhaps more surprisingly, regardless of what drugs are now available, this pattern continues in the present day. It seems that as much as medicine and science have changed since the 18th century, many characterizations of masculinity and femininity have remained the same. With the inception of modern medicine in the Victorian Era, sex became an object of scientific study. And from the earliest sexology texts onward, gender differences have been assumed and discursively reproduced. In early medical textbooks, women were depicted as sexually deviant—the vagina was thought to be an “inverted” penis, and women were framed as inferior, sometimes as constitutionally asexual, or, at the very least, as innately lower in sexual desire than men. Female sexuality was also characterized as complex, complicated, wayward, and peculiar—nothing like the straightforward, potent, goal-oriented, and virile sexuality of men.
See also
Food and Drug Administration (FDA)—including a testosterone patch, a hormonal nasal spray, and what will now certainly go down in history as the most successful—an ingestable oral tablet[2]. The image shows a small pink-peach colored pill laying on top of a brochure for Sprout Pharmaceuticals. Some have called this pill, prescribed to enhance women’s sexual desire, the “pink” or “female” Viagra—but, thoughtful citizens and potential consumers might ask: how similar are the two drugs, in terms of chemical make-up, design, and prescribed treatment regimen? Upon comparing the two medications, it becomes clear that they are in fact far from equivalent (or even similar). In addition to contrasting the mechanisms of the two drugs, it might be equally important to examine the assumptions being made about men’s and women’s sexuality as these drugs are produced and consumed, or the theories of sexuality and sexual difference being administered to premature ejaculation medicine patients alongside the drugs themselves.
TNvitamins Extra Strength Super Cranberry Supplement 30,000 Mg Capsules, Supports Urinary Tract Health, 90 Count
In order to uncover these hidden theories of sexual difference, I take a look at how men’s and women’s sexualities are configured within contemporary—and more antiquated—medical and scientific discourses. Through a brief exploratory comparison, one thing becomes evident—women have consistently been framed as very different from men, sexually, and this has undoubtedly impacted our experience of our own sexual self-determination, agency, desire, and pleasure. And, perhaps more surprisingly, regardless of what drugs are now available, this pattern continues in the present day. It seems that as much as medicine and science have changed since the 18th century, many characterizations of masculinity and femininity have remained the same. With the inception of modern medicine in the Victorian Era, sex became an object of scientific study. These ideas about men’s and women’s sexualities have persisted in a variety of guises through many different psychological and psychiatric paradigms—from sexology, to psychoanalysis, to our current biopsychiatric and neuroscience-based explanations and treatments. Within contemporary sexual medicine and studies of pathology, men are perceived as disproportionately likely to suffer from physiological ailments such as erectile disorder, whereas women are understood as more likely to suffer from psychological blocks to optimal sexual enjoyment. And in our current quick-fix climate, these perceived differences in sexuality translate into drastically different framings and treatments of sexual dysfunction for men and for women, with gender-differentiated consequences for sexual health, attitudes, and relationships—among both “dysfunctional” and “healthy” populations.
THR Newsletters
And from the earliest sexology texts onward, gender differences have been assumed and discursively reproduced. In early medical textbooks, women were depicted as sexually deviant—the vagina was thought to be an “inverted” penis, and women were framed as inferior, sometimes as constitutionally asexual, or, at the very least, as innately lower in sexual desire than men. Female sexuality was also characterized as complex, complicated, wayward, and peculiar—nothing like the straightforward, potent, goal-oriented, and virile sexuality of men. These ideas about men’s and women’s sexualities have persisted in a variety of guises through many different psychological and psychiatric paradigms—from sexology, to psychoanalysis, to our current biopsychiatric and neuroscience-based explanations and treatments. Within contemporary sexual medicine and studies of pathology, men are perceived as disproportionately likely to suffer from physiological ailments such as erectile disorder, whereas women are understood as more likely to suffer from psychological blocks to optimal sexual enjoyment.
by Horbaach $16.22
And in our current quick-fix climate, these perceived differences in sexuality translate into drastically different framings and treatments of sexual dysfunction for men and for women, with gender-differentiated consequences for sexual health, attitudes, and relationships—among both “dysfunctional” and “healthy” populations. Take, for example, the new gender-specific sexual desire disorders in clinical psychology literature, and their corresponding gendered models of desire and sexual response. In the newest Diagnostic and Statistical Manual of Mental Disorders (DSM-5, 2013)—what is generally understood to be the contemporary psychiatrist’s “bible”—the diagnosis of “Female Sexual Interest/Arousal Disorder” (FSIAD) includes lack of sexual receptivity[3] as a core component of sexual dysfunction—and is diagnosed in women only. This new female-specific diagnosis did away with the older gender-neutral “Hypoactive Sexual Desire Disorder” or HSDD; before the publication of the DSM-5, HSDD was the diagnosis that both low-desiring men and low-desiring women received. Now, for the first time in the history of the Manual, the diagnoses are gender-differentiated, with low-desiring women receiving the diagnosis of FSIAD, including its “lack of receptivity [to a partner]” criterion, and men receiving the much simpler and more stream-lined diagnosis of regular old HSDD (now “Male Hypoactive Sexual Desire Disorder” or MHSDD). Take, for example, the new gender-specific sexual desire disorders in clinical psychology literature, and their corresponding gendered models of desire and sexual response. In the newest Diagnostic and Statistical Manual of Mental Disorders (DSM-5, 2013)—what is generally understood to be the contemporary psychiatrist’s “bible”—the diagnosis of “Female Sexual Interest/Arousal Disorder” (FSIAD) includes lack of sexual receptivity[3] as a core component of sexual dysfunction—and is diagnosed in women only.
it’s harder for me to become aroused
The Pink Pill, produced by Julie Bristow of Catalyst and Abby Greensfelder of Everywoman Studios, will have a world premiere at DOC NYC on Nov. 15. Before that, Sphere Abacus, handling global sales, will shop the film to U.S. and other international buyers at MIPCOM next week. And Paramount+ will release the documentary in Canada in early 2026.
HALLMENOPAUS - Menopause Supplements for Women - 30 Capsules - 30 Servings - Hormonal, Estrogen Balance & Mood - Soy Isoflavones & Ipriflavona - Dietary Supplement - Hallusa Natural $24.99
Eckert’s ultimate victory in securing regulatory approval for Addyi underpins the documentary’s revelations about gender bias at the FDA as a drug that claimed to improve female pleasure was dismissed as trivial or even dangerous. “I am thankful for the trust that I was given by the people I spoke to in the making of this film, and proud to spotlight those who challenge the inequity and systemic bias against women’s and marginalized bodies’ needs, especially in something as fundamental as sexual health,” Chin-Yee said in a statement as she hopes her film sparks a wider conversation about a more equitable healthcare system. The film is executive produced by Bristow, Greensfelder, Chin-Yee, Vibika Bianchi and Knix founder and president Joanna Griffiths, a backer of Docs for Change, a collaboration between Catalyst, the Toronto-based studio, and Knix Fund, the charity arm of the Knix brand. Sign up for THR news straight to your inbox every day This long-form scholarly blog entry is authored by Dr. Alyson K. This new female-specific diagnosis did away with the older gender-neutral “Hypoactive Sexual Desire Disorder” or HSDD; before the publication of the DSM-5, HSDD was the diagnosis that both low-desiring men and low-desiring women received. Now, for the first time in the history of the Manual, the diagnoses are gender-differentiated, with low-desiring women receiving the diagnosis of FSIAD, including its “lack of receptivity [to a partner]” criterion, and men receiving the much simpler and more stream-lined diagnosis of regular old HSDD (now “Male Hypoactive Sexual Desire Disorder” or MHSDD). Five versions of the Diagnositc and Statistical Manual of Mental Disorders (the DSM) are shown, with the most recent of them, the DSM-5, in the foreground. These disorders and their diagnostic patterns are crucial to critically analyze, as estimates of diagnosably low sexual desire in premenopausal women currently range from around 10% to more than 25% of the population, and women receive the vast majority of low desire diagnoses. Does this all sound very, very complicated? Well, that’s because it is—perhaps intentionally so, as a purported reflection of the complicated nature of female sexuality. The FSIAD diagnostic framework, including claims regarding neurobiologically hardwired feminine responsiveness, receptivity, flexibility, and complexity is based on an “alternative sexual response model” for women. This new model originally emerged in clinical psychology in the late 1990s, and maintains the idea that women are more sexually complex (confusing? The model is applied to women only, as a so-called “woman-centric” “corrective” to the Human Sexual Response Cycle, or HSRC, originally instituted in 1966 by Masters and Johnson.
| Country | Regulations Status | Approval Process | Regulatory Body |
|---|---|---|---|
| USA | FDA regulates dietary supplements | Requires safety testing before sale | FDA |
| EU | Classified as food supplements | Compliance with EFSA standards | EFSA, local authorities |
| Australia | TGA oversees supplement safety | Pre-market assessment | TGA |
| Canada | Health Canada regulates dietary supplements | Licensing required | Health Canada |
The HSRC, a linear model of sexual response, posits that orgasm invariably results from sexual stimulation—or that it ought to, in sexually healthy or “normal” individuals. It has been the primary medical model of sexual response for both sexes since its inception, but the validity of the HSRC has recently been challenged by some psychologists who state that it does not accurately fit “the female experience of sex.” While a revision to the linear HSRC may indeed be timely (for everyone! ), it is important to consider how an “alternative sexual response model” designed for women only and based on a categorically feminine framing of sexual health and pathology preserves the myth that women’s desire is inherently different from men’s desire, and perpetuates the notions that women are: 1.) less driven than men by spontaneous or internal sexual needs 2.) more likely than men to engage in cost-benefit analyses of sex as they consider possible non-sexual rewards or incentives to be gained from a given act (thus the shift to the language of “interest” in FSIAD) 3.) more likely than men to feel desire only or primarily when “triggered” by an initiating—and tacitly male—partner. Insofar as it supports and is supported by the alternative female sexual response model, the FSIAD diagnosis continues to perpetuate these myths, purporting that because women are less sexual than men are by nature, a lack of spontaneous desire on its own should not lead to a low desire diagnosis for them. According to this logic, instead, it is only the women who are unable to motivate a rational, incentive-based “interest” in sex who should receive the diagnosis of FSIAD. Unlike the “unresponsive” (dare we say frigid?) woman, then, a healthy, sexually functional, or normal woman is understood to be rationally receptive and responsive to her partner’s overtures, eventually priming herself to engage in sex with him, to bring her low-desiring mind into line with her lubricated and vasocongested body.
What Makes The Pink Pill So Controversial?
Spurgas, Assistant Professor of Sociology at SIUE. Dr. Spurgas regularly teaches courses in the Women’s Studies minor including Gender & Society. Her research expertise lies primarily in medical sociology, which uses sociological analysis to examine medical organizations and institutions including the production of knowledge within medicine, the actions and interactions of healthcare professionals, and the social or cultural effects of medical practice. In this blog entry, Dr.
Non-GMO
Spurgas reflects on how medicine interacts with sexuality and gender norms by focusing on the notion of a “female Viagra.” What ideas about sexuality, she asks, do we reinforce by how we both diagnose and treat “low female desire”? Is it a problem that part of the technical diagnostic criteria involve how receptive a woman is to her partner’s advances? Why does the treatment for this target women’s minds (their desire), when men’s treatments for sexual dysfunction target their physical performance? Since the unprecedented success of Viagra[1] in the late 1990s, pharmaceutical companies in the United States and abroad have been on a tortuous search to corner the market in a drug to treat women’s sexual dysfunction. A variety of methods have been dreamed up, tested in clinical trials, and evaluated by the U.S.
- Mythology and Folklore of Blue Pillmen
- Understanding Apcalis SX Oral Jelly – Beyond Erectile Dysfunction and its Impacts on Men’s Health
- Ayurvedic Medicine for Sex Stamina: Natural Tips and Herbs for Enhanced Vitality
- Generic Priligy 30 Mg (Dapoxetine)
- Apcalis SX20 Tablet
- Viagra para mujeres: qué es, cómo funciona y cuándo tomar
- Levitra Farmaco